Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen

Intellia Therapeutics (NASDAQ:NTLA) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

A number of other equities analysts have also recently issued reports on the company. Leerink Partners boosted their price objective on Intellia Therapeutics from $27.00 to $29.00 and gave the company an “outperform” rating in a report on Tuesday. Canaccord Genuity Group decreased their target price on Intellia Therapeutics from $54.00 to $48.00 and set a “buy” rating for the company in a research report on Tuesday. Royal Bank Of Canada boosted their target price on shares of Intellia Therapeutics from $9.00 to $15.00 and gave the company a “sector perform” rating in a research note on Tuesday. Oppenheimer set a $27.00 price target on shares of Intellia Therapeutics in a report on Friday, November 7th. Finally, Citizens Jmp raised their price target on shares of Intellia Therapeutics from $21.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Tuesday. Eleven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Intellia Therapeutics has an average rating of “Hold” and an average price target of $19.59.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock opened at $13.44 on Friday. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $28.25. The firm has a market capitalization of $1.59 billion, a P/E ratio of -3.51 and a beta of 2.10. The company’s 50-day moving average is $12.33 and its 200 day moving average is $13.12.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.16. The business had revenue of $23.02 million during the quarter, compared to analyst estimates of $12.17 million. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The company’s revenue for the quarter was up 78.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.27) earnings per share. Research analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In other news, EVP Birgit C. Schultes sold 8,508 shares of Intellia Therapeutics stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $78,358.68. Following the transaction, the executive vice president directly owned 98,533 shares in the company, valued at approximately $907,488.93. This trade represents a 7.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO John M. Leonard sold 34,146 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $314,484.66. Following the completion of the transaction, the chief executive officer directly owned 1,013,339 shares of the company’s stock, valued at approximately $9,332,852.19. The trade was a 3.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 53,051 shares of company stock valued at $488,600. 3.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Intellia Therapeutics

Several hedge funds have recently modified their holdings of the company. Comerica Bank grew its position in shares of Intellia Therapeutics by 45.8% in the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after buying an additional 901 shares during the last quarter. Headlands Technologies LLC purchased a new stake in Intellia Therapeutics during the second quarter valued at approximately $26,000. Blue Bell Private Wealth Management LLC acquired a new stake in Intellia Therapeutics in the third quarter valued at approximately $30,000. Caitong International Asset Management Co. Ltd acquired a new stake in Intellia Therapeutics in the third quarter valued at approximately $30,000. Finally, Advisory Services Network LLC purchased a new position in Intellia Therapeutics in the third quarter worth $33,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

Key Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Jefferies (or another firm) boosted its price target to $30, a sizable upward revision that supports upside expectations for NTLA. Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $30.00
• Positive Sentiment: A separate analyst raised the price target to $28, reinforcing bullish momentum from multiple houses. Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $28.00
• Positive Sentiment: Leerink Partners published a note saying NTLA’s stock price is expected to rise, adding another bullish voice that can attract momentum buyers. Intellia Therapeutics (NASDAQ:NTLA) Stock Price Expected to Rise, Leerink Partners Analyst Says
• Positive Sentiment: Wells Fargo reiterated a strong forecast for price appreciation, supporting investor confidence in NTLA’s longer-term prospects. Wells Fargo & Company Forecasts Strong Price Appreciation for Intellia Therapeutics (NASDAQ:NTLA) Stock
• Positive Sentiment: Royal Bank of Canada raised its target to $15, another incremental upgrade that may help lift consensus sentiment. Royal Bank Of Canada Boosts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $15.00
• Neutral Sentiment: Intellia announced inducement equity grants to six new employees under its 2024 Inducement Plan — routine hiring news that signals talent additions but also dilution/cost. Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Neutral Sentiment: Analysts’ consensus rating sits at “Hold,” indicating mixed professional views despite recent bullish notes. Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of “Hold” from Analysts
• Neutral Sentiment: A valuation/deep-dive piece reviews NTLA’s rebound and financials (revenue growth vs. large losses), useful context for longer-term investors but not a near-term catalyst. A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound
• Negative Sentiment: HC Wainwright lowered its earnings estimates for NTLA, a negative data point that may weigh on near-term expectations. HC Wainwright Brokers Reduce Earnings Estimates for NTLA
• Negative Sentiment: Canaccord Genuity trimmed its outlook for NTLA, adding to the minority of bearish analyst moves. Canaccord Genuity Group Has Lowered Expectations for Intellia Therapeutics (NASDAQ:NTLA) Stock Price

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.